Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
Status:
Not yet recruiting
Trial end date:
2028-03-13
Target enrollment:
Participant gender:
Summary
The overall purpose of this two-part study is to evaluate the efficacy, safety and
tolerability of iptacopan (LNP023) in addition to standard of care treatment.